Myc

Other Cell Cycle Inhibitors

• Featured Inhibitors
• Inhibitors (14)
• Modulator (1)
• Agonist (1)

Cat.No.	Product Name	Information	Product Use Citations	Product Validations
S8906	MYCi975	MYCi975 (NUCC-0200975) is a potent, selective and orally active inhibitor of MYC that disrupts MYC/MAX interaction, promotes MYC T58 phosphorylation and MYC degradation, and impairs MYC driven gene expression. This compound exhibits potent anti-tumour activities.	Nature, 2025, 646(8085):707-715 Cell Rep, 2025, 44(6):115722 Mol Cancer Ther, 2025, 10.1158/1535-7163.MCT-25-0136
S9667	Inobrodib (CCS-1477)	Inobrodib (CCS1477; CBP-IN-1; CBP/p300-IN-4) is a potent and selective inhibitor of p300/CBP bromodomain. CCS1477 works by inhibiting the expression and function of the Androgen Receptor (AR), as well as inhibiting c-Myc.	Nat Genet, 2025, 57(10):2468-2481 Nat Commun, 2025, 16(1):4133 PLoS Pathog, 2025, 21(9):e1013073
S8762	dBET6	dBET6 is a highly cell-permeable PROTAC degrader of BET bromodomains with an IC50 of 14 nM for BRD4 binding. dBET6 also induces c-MYC downregulation and apoptosis.	Sci Adv, 2025, 11(49):eadu2292 J Nanobiotechnology, 2024, 22(1):692 J Pathol, 2024, 262(1):37-49
S7153	10058-F4	10058-F4 is a c-Myc inhibitor that specifically inhibits the c-Myc-Max interaction and prevents transactivation of c-Myc target gene expression. 10058-F4 promotes a caspase-3-dependent apoptosis and modulates autophagy.	Nat Commun, 2025, 16(1):138 Int J Biol Sci, 2025, 21(6):2762-2779 Cell Death Dis, 2025, 16(1):601
S8426	10074-G5	10074-G5 is a c-Myc inhibitor that binds to and distorts the bHLH-ZIP domain of c-Myc (Kd = 2.8 µM), thereby inhibiting c-Myc/Max heterodimer formation and inhibiting its transcriptional activity (IC50 = 146 µM).	J Exp Clin Cancer Res, 2025, 44(1):70 Acta Neuropathol Commun, 2025, 13(1):139 Cell Death Dis, 2024, 15(11):861
S8905	MYCi361	MYCi361 is a MYC inhibitor that engages MYC inside cells, disrupts MYC/MAX dimers, and impairs MYC-driven gene expression. This compound binds to MYC with Kd of 3.2 μM. It suppresses in vivo tumour growth, increases tumour immune cell infiltration, upregulates PD-L1 on tumours, and sensitises tumours to anti-PD1 immunotherapy.	Cells, 2025, 14(10)709 RSC Chem Biol, 2025, 10.1039/d5cb00093a Haematologica, 2024, 109(12):3989-4006
S9807	EN4	EN4, a covalent ligand that targets cysteine 171 (C171) of MYC, is selective for c-MYC over N-MYC and L-MYC. This compound inhibits MYC transcriptional activity, downregulates MYC targets, and impairs tumorigenesis.	Cell Rep, 2025, 44(3):115327 Nat Commun, 2024, 15(1):3905 Cell Rep, 2023, 42(11):113198
E1022	DMBA chemical (7,12-Dimethylbenz[a]anthracene)	7,12-Dimethylbenz[a]anthracene (DMBA) is an immunosuppressor as well as a potent organ-specific carcinogen.	bioRxiv, 2024, 2024.09.21.613572
S6963	APTO-253	APTO-253 (LOR-253, LT-253) inhibits c-Myc expression and selectively induces CDKN1A (p21), promotes G0-G1 cell-cycle arrest, and triggers apoptosis in acute myeloid leukaemia (AML) cells. This compound is also an inducer of KLF4 (Krüppel-like factor 4).	Cell Commun Signal, 2023, 21(1):94
S0249	Mycro 3	Mycro 3 is a potent and selective inhibitor of c-Myc in whole cell assays. This compound also shows weak inhibitory activity against AP-1.	J Biol Chem, 2025, S0021-9258(25)00377-1
1 2